Evidence map›Paper›PMID 40478800›Full record

ArticlePloS one2025

The tumor suppressor FAT1 controls YAP/TAZ protein degradation and tumor cell proliferation through E3 ligase MIB2.

Rui Li, Boris Strilic, Young-June Jin, Jingchen Shao, Yundong Peng, Lei Wang, Qi Quan, Zhiyong Wang, Johannes Graumann, J Silvio Gutkind and 2 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rui LiDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Boris StrilicDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Young-June JinDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Jingchen ShaoDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID https://orcid.org/0000-0002-5305-2344
Yundong PengDepartment of Cardiac Development and Remodeling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Lei WangDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Qi QuanDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Zhiyong WangMoores Cancer Center, University of California, San Diego, La Jolla, California, United States of America.
Johannes GraumannBiomolecular Mass Spectrometry Service Group, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
J Silvio GutkindMoores Cancer Center, University of California, San Diego, La Jolla, California, United States of America.
Nina WettschureckDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.
Stefan OffermannsDepartment of Pharmacology, Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany.ORCID https://orcid.org/0000-0001-8676-6805

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

FAT1 is a tumor suppressor gene encoding the protocadherin FAT1, which has been found to be mutated in different types of human cancers with the highest frequency in head and neck squamous cell carcinoma (HNSCC). However, through which mechanisms mutations of FAT1 lead to tumor progression is incompletely understood. Here, we report that loss of FAT1 in various tumor cells, including HNSCC cells, resulted in increased protein levels of the transcriptional regulators YAP and TAZ. This was sufficient to lead to increased expression of YAP/TAZ target genes and to increased tumor cell proliferation. We found that elevated YAP/TAZ activity after loss of FAT1 was due to decreased YAP/TAZ protein degradation, which could be rescued by expression of the intracellular part of FAT1. When analyzing the interactome of the cytoplasmic part of FAT1 in tumor cells, we identified the E3 ubiquitin ligase Mind Bomb-2 (MIB2) as an interaction partner. Suppression of MIB2 expression in various tumor cells led to same effects as loss of FAT1 expression, including a decrease in YAP and TAZ ubiquitination, and degradation as well as an increase in YAP/TAZ protein levels and expression of YAP/TAZ target genes. Similarly, Hela cells or HNSCCs with suppressed MIB2 expression resembled FAT1 defective tumor cells showing faster proliferation in vitro as well as increased tumor growth in vivo compared to control cells. Our study identifies a mechanism by which YAP/TAZ levels are kept low through FAT1/MIB2-mediated protein degradation and shows that tumor progression resulting from mutation of tumor suppressor FAT1 involves loss of MIB2-dependent degradation of YAP and TAZ.

Indexed as

Adaptor Proteins, Signal TransducingCadherinsIntracellular Signaling Peptides and ProteinsPhosphoproteinsTranscription FactorsUbiquitin-Protein LigasesAnimalsCarcinoma, Squamous CellCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansProteolysisTranscriptional Coactivator with PDZ-Binding Motif ProteinsYAP-Signaling ProteinsAdaptor Proteins, Signal TransducingCadherinsFAT1 protein, humanIntracellular Signaling Peptides and ProteinsPhosphoproteinsTranscriptional Coactivator with PDZ-Binding Motif ProteinsTranscription FactorsUbiquitin-Protein LigasesWWTR1 protein, humanYAP1 protein, humanYAP-Signaling Proteins

Identifiers

PMID40478800
PMCPMC12143506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.